Table of Content

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS & EXCLUSIONS 34
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 BIOMARKERS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED 35
1.4 CURRENCY 35
1.5 LIMITATIONS 35
1.6 STAKEHOLDERS 36
1.7 SUMMARY OF CHANGES 36
1.7.1 RECESSION IMPACT 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH APPROACH 37
FIGURE 2 BIOMARKERS MARKET: RESEARCH DESIGN 37
2.1.1 SECONDARY RESEARCH 37
2.1.1.1 Secondary sources 39
2.1.2 PRIMARY RESEARCH 39
2.1.2.1 Primary sources 40
2.1.2.2 Primary sources 41
2.1.2.3 Breakdown of primaries 41
FIGURE 3 BIOMARKERS MARKET: BREAKDOWN OF PRIMARIES 41
2.2 MARKET SIZE ESTIMATION 42
FIGURE 4 BIOMARKERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 42
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022 43
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF ALL BIOMARKER PRODUCTS IN THE MARKET 43
FIGURE 7 KEY INDUSTRY INSIGHTS 45
FIGURE 8 BIOMARKERS MARKET: CAGR PROJECTIONS, 2023–2028 46
FIGURE 9 BIOMARKERS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 46
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 47
FIGURE 10 DATA TRIANGULATION METHODOLOGY 48
2.4 RESEARCH LIMITATIONS 48
2.5 RESEARCH ASSUMPTIONS 49
2.6 RISK ANALYSIS 49
2.7 RECESSION IMPACT 49
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 49
3 EXECUTIVE SUMMARY 51
FIGURE 11 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 51
FIGURE 12 BIOMARKERS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 52
FIGURE 13 BIOMARKERS MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD MILLION) 52
FIGURE 14 BIOMARKERS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 53
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF BIOMARKERS MARKET 54
4 PREMIUM INSIGHTS 55
4.1 BIOMARKERS MARKET OVERVIEW 55
FIGURE 16 GROWING IMPORTANCE OF COMPANION DIAGNOSTICS EXPECTED TO DRIVE BIOMARKERS MARKET 55
4.2 ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE AND BY COUNTRY (2022) 56
FIGURE 17 CONSUMABLES ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022 56
4.3 BIOMARKERS MARKET, BY REGION, 2022 57
FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 57
5 MARKET OVERVIEW 58
5.1 MARKET DYNAMICS 58
FIGURE 19 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58
5.1.1 MARKET DRIVERS 59
5.1.1.1 Growing importance of companion diagnostics 59
5.1.1.2 Increase in global prevalence of cancer 60
TABLE 2 NUMBER OF NEW CANCER CASES, BY TYPE, 2020–2040 60
TABLE 3 CANCER INCIDENCE, BY REGION (2040) 61
5.1.1.3 Increase in funds and grants for biomarker research 61
5.1.1.4 Continuous product innovations 62
TABLE 4 PRODUCT LAUNCHES, 2020?2022 62
5.1.2 RESTRAINTS 63
5.1.2.1 High capital investments and lengthy timelines for biomarker development 63
TABLE 5 TIME FRAME FOR BIOMARKER DEVELOPMENT 63
5.1.3 OPPORTUNITIES 64
5.1.3.1 Personalized medicine 64
5.1.3.2 Emerging economies 65
5.1.4 CHALLENGES 65
5.1.4.1 Challenges associated with biomarker validation 65
5.1.4.2 Technical issues related to sample collection and storage 65
?
5.2 REGULATORY ASSESSMENT 66
5.2.1 INTRODUCTION 66
5.2.2 BIOMARKER QUALIFICATION IN US 66
5.2.3 BIOMARKER QUALIFICATION IN EUROPE 66
5.3 VALUE CHAIN ANALYSIS 67
FIGURE 20 BIOMARKERS MARKET: VALUE CHAIN ANALYSIS 67
5.4 TECHNOLOGICAL ANALYSIS 67
5.4.1 IMMUNOASSAYS 68
5.4.1.1 Immunohistochemistry (IHC) 68
5.4.1.2 Flow cytometry 68
5.4.1.3 Flow cytometry ELISA 68
5.4.2 NEXT-GENERATION SEQUENCING (NGS) 68
5.4.3 POLYMERASE CHAIN REACTION (PCR) 69
5.4.4 IN SITU HYBRIDIZATION 69
5.4.5 MICROARRAYS 69
5.4.6 MASS SPECTROMETRY 70
5.5 PRICING ANALYSIS 70
TABLE 6 SELLING PRICE OF BIOMARKERS BY TOP PLAYERS 70
5.6 PATENT ANALYSIS 72
FIGURE 21 PATENT APPLICATIONS FOR BIOMARKERS MARKET, JANUARY 2012–DECEMBER 2022 72
5.7 BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 73
FIGURE 22 BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 74
5.7.1 KEY INFLUENCERS 74
5.8 ECOSYSTEM ANALYSIS 75
TABLE 7 BIOMARKERS MARKET: SUPPLY CHAIN ECOSYSTEM 75
5.9 KEY CONFERENCES AND EVENTS, 2023–2024 76
TABLE 8 BIOMARKERS MARKET: LIST OF CONFERENCES AND EVENTS 76
5.10 PORTER’S FIVE FORCES ANALYSIS 78
5.10.1 IMPACT OF PORTER’S FIVE FORCES ON BIOMARKERS MARKET 78
5.10.2 INTENSITY OF COMPETITIVE RIVALRY 78
5.10.3 BARGAINING POWER OF SUPPLIERS 78
5.10.4 BARGAINING POWER OF BUYERS 79
5.10.5 THREAT OF SUBSTITUTES 79
5.10.6 THREAT OF NEW ENTRANTS 79
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 79
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOMARKERS 79
5.11.2 BIOMARKERS MARKET: BUYING CRITERIA 80
FIGURE 24 KEY BUYING CRITERIA FOR END USERS 80
5.12 ECOSYSTEM ANALYSIS OF BIOMARKERS MARKET 80
FIGURE 25 BIOMARKERS MARKET: ECOSYSTEM ANALYSIS 80
5.12.1 ROLE IN ECOSYSTEM 81
5.13 REVENUE SHIFT FOR BIOMARKERS MARKET 81
FIGURE 26 BIOMARKERS MARKET: REVENUE SHIFT 81
6 BIOMARKERS MARKET, BY PRODUCT & SERVICE 82
6.1 INTRODUCTION 83
TABLE 9 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 83
6.2 CONSUMABLES 83
6.2.1 NEED FOR HIGH-FREQUENCY PURCHASE OF CONSUMABLES TO DRIVE MARKET GROWTH 83
TABLE 10 BIOMARKER CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION) 84
TABLE 11 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 12 EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 13 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 14 ROW: BIOMARKER CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION) 85
6.3 SERVICES 85
6.3.1 GRADUAL SHIFT FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING OF SERVICES TO SUPPORT MARKET GROWTH 85
TABLE 15 BIOMARKER SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 86
TABLE 16 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 17 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 18 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 19 ROW: BIOMARKER SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 87
6.4 SOFTWARE 87
6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO SUPPORT MARKET GROWTH 87
TABLE 20 BIOMARKER SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION) 88
TABLE 21 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 22 EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 23 ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 24 ROW: BIOMARKER SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION) 89
?
7 BIOMARKERS MARKET, BY TYPE 90
7.1 INTRODUCTION 91
TABLE 25 BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 91
7.2 EFFICACY BIOMARKERS 91
TABLE 26 EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 92
TABLE 27 EFFICACY BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 92
TABLE 28 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 29 EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 30 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 31 ROW: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 93
7.2.1 PREDICTIVE BIOMARKERS 94
7.2.1.1 Wide applications of predictive biomarkers in personalized medicine and companion diagnostics to drive market 94
TABLE 32 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 94
TABLE 33 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 34 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 35 ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 36 ROW: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 95
7.2.2 SURROGATE BIOMARKERS 96
7.2.2.1 Use of surrogate biomarkers helps accelerate drug development and shorten timelines for regulatory approval 96
TABLE 37 SURROGATE BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 38 NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 39 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 40 ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 41 ROW: SURROGATE BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 97
7.2.3 PHARMACODYNAMIC BIOMARKERS 98
7.2.3.1 Increasing utilization of pharmacodynamic biomarkers in selection and optimization of drug doses to boost market 98
TABLE 42 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 43 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 44 EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 45 ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 46 ROW: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 99
7.2.4 PROGNOSTIC BIOMARKERS 100
7.2.4.1 Prognostic biomarkers help predict recurrence of diseases 100
TABLE 47 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 48 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 49 EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 50 ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 51 ROW: PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 101
7.3 SAFETY BIOMARKERS 102
7.3.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT TO FUEL MARKET GROWTH 102
TABLE 52 SAFETY BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 53 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 54 EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 55 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 56 ROW: SAFETY BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 104
7.4 VALIDATION BIOMARKERS 104
7.4.1 VALIDATION BIOMARKERS ENABLE EVALUATION OF DIAGNOSTIC SYSTEMS 104
TABLE 57 VALIDATION BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 58 NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 59 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 60 ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 61 ROW: VALIDATION BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 106
8 BIOMARKERS MARKET, BY DISEASE INDICATION 107
8.1 INTRODUCTION 108
TABLE 62 BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 108
?
8.2 CANCER 108
8.2.1 INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET 108
TABLE 63 LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER 109
TABLE 64 BIOMARKERS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 65 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 66 EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 67 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 68 ROW: BIOMARKERS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 111
8.3 INFECTIOUS DISEASES 111
8.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE DEMAND FOR BIOMARKERS 111
TABLE 69 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 112
TABLE 70 NORTH AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 71 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 72 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 73 ROW: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 113
8.4 IMMUNOLOGICAL DISORDERS 113
8.4.1 INCREASING ADOPTION OF BIOMARKERS FOR VARIOUS IMMUNOLOGICAL DISORDERS TO DRIVE MARKET 113
TABLE 74 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS 114
TABLE 75 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 76 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 77 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 78 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 79 ROW: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 116
8.5 NEUROLOGICAL DISORDERS 116
8.5.1 IMMUNOASSAYS WIDELY USED IN DIAGNOSIS OF NEUROLOGICAL DISORDERS 116
TABLE 80 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 81 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 82 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 83 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 84 ROW: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 118
8.6 CARDIOVASCULAR DISORDERS 118
8.6.1 GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS 118
TABLE 85 BIOMARKERS FOR CARDIOVASCULAR DISORDERS 118
TABLE 86 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2021–2028 (USD MILLION) 119
TABLE 87 NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 88 EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 89 ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 90 ROW: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2021–2028 (USD MILLION) 120
8.7 OTHER DISEASE INDICATIONS 120
TABLE 91 BIOMARKERS FOR RENAL DISORDERS 121
TABLE 92 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 93 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 94 EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 95 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 96 ROW: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 123
9 BIOMARKERS MARKET, BY APPLICATION 124
9.1 INTRODUCTION 125
TABLE 97 BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 125
9.2 DIAGNOSTICS 125
9.2.1 INCREASING USE OF BIOMARKERS FOR DIAGNOSIS OF VARIOUS DISEASES TO DRIVE GROWTH 125
TABLE 98 BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 99 NORTH AMERICA: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 100 EUROPE: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 101 ASIA PACIFIC: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 102 ROW: BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 127
9.3 DRUG DISCOVERY & DEVELOPMENT 127
9.3.1 BIOMARKERS PLAY KEY ROLE AS BIOLOGICAL INDICATORS IN DEVELOPMENT OF NEW DRUGS 127
TABLE 103 BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 104 NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 105 EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 106 ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 107 ROW: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 129
9.4 PERSONALIZED MEDICINE 130
9.4.1 INCREASING APPLICATIONS OF BIOMARKERS IN PERSONALIZED MEDICINE TO DRIVE MARKET 130
TABLE 108 SELECTED PERSONALIZED MEDICINE DRUGS AND RELEVANT BIOMARKERS 130
TABLE 109 BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 110 NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 111 EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 112 ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 113 ROW: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION) 132
9.5 DISEASE RISK ASSESSMENT 132
9.5.1 BIOMARKERS WIDELY USED FOR TOXICITY CHARACTERIZATION IN DISEASE DIAGNOSIS AND DRUG DEVELOPMENT PROCESSES 132
TABLE 114 BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 115 NORTH AMERICA: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 116 EUROPE: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 117 ASIA PACIFIC: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 118 ROW: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY REGION, 2021–2028 (USD MILLION) 134
9.6 OTHER APPLICATIONS 134
TABLE 119 BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 120 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 121 EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 122 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 123 ROW: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 136
10 BIOMARKERS MARKET, BY REGION 137
10.1 INTRODUCTION 138
TABLE 124 BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 138
10.2 NORTH AMERICA 139
FIGURE 27 NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT 139
TABLE 125 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 126 NORTH AMERICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 140
TABLE 127 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 128 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 129 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 141
TABLE 130 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 142
10.2.1 US 142
10.2.1.1 US expected to dominate biomarkers market in North America during forecast period 142
TABLE 131 US: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 143
TABLE 132 US: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 133 US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 134 US: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 144
TABLE 135 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 144
10.2.2 CANADA 144
10.2.2.1 Increasing incidence of cancer to drive growth of biomarker research 144
TABLE 136 CANADA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145
TABLE 137 CANADA: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 138 CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 139 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 140 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 146
10.2.3 NORTH AMERICA: RECESSION IMPACT 147
?
10.3 EUROPE 147
TABLE 141 EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 142 EUROPE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 148
TABLE 143 EUROPE: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 144 EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 145 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 149
TABLE 146 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 150
10.3.1 GERMANY 150
10.3.1.1 Increase in government funding for biomarker research to drive market growth 150
TABLE 147 GERMANY: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 150
TABLE 148 GERMANY: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 149 GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 150 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 151
TABLE 151 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 152
10.3.2 UK 152
10.3.2.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers 152
TABLE 152 UK: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 152
TABLE 153 UK: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 154 UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 155 UK: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 153
TABLE 156 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 154
10.3.3 FRANCE 154
10.3.3.1 Increasing government investments in genomics and proteomics research to drive market growth 154
TABLE 157 FRANCE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 154
TABLE 158 FRANCE: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 159 FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 160 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155
TABLE 161 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 156
10.3.4 ITALY 156
10.3.4.1 Increasing life science R&D funding to drive market growth 156
TABLE 162 ITALY: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 156
TABLE 163 ITALY: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 164 ITALY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 165 ITALY: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 157
TABLE 166 ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 158
10.3.5 SPAIN 158
10.3.5.1 Growing focus on cancer biomarkers to propel market growth 158
TABLE 167 SPAIN: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 158
TABLE 168 SPAIN: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 169 SPAIN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 170 SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 159
TABLE 171 SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 160
10.3.6 REST OF EUROPE 160
TABLE 172 REST OF EUROPE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 160
TABLE 173 REST OF EUROPE: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 174 REST OF EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 175 REST OF EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 161
TABLE 176 REST OF EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 162
10.3.7 EUROPE: RECESSION IMPACT 162
10.4 ASIA PACIFIC 163
TABLE 177 ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 178 ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 163
TABLE 179 ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 180 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 181 ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 164
TABLE 182 ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 165
10.4.1 CHINA 165
10.4.1.1 Increasing burden of diseases and growing focus on development of novel drugs to drive demand for biomarkers 165
TABLE 183 CHINA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 165
TABLE 184 CHINA: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 185 CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 186 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 166
TABLE 187 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 167
10.4.2 JAPAN 167
10.4.2.1 Strategic collaborations with leading pharmaceutical companies to drive market 167
TABLE 188 JAPAN: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 168
TABLE 189 JAPAN: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 190 JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 191 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 169
TABLE 192 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 169
10.4.3 INDIA 169
10.4.3.1 Growing prevalence of target diseases expected to support biomarkers market 169
TABLE 193 INDIA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 170
TABLE 194 INDIA: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 195 INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 196 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 171
TABLE 197 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 171
10.4.4 REST OF ASIA PACIFIC 171
TABLE 198 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 172
TABLE 199 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 200 REST OF ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 201 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 173
TABLE 202 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 173
10.4.5 ASIA PACIFIC: RECESSION IMPACT 173
10.5 REST OF THE WORLD 174
TABLE 203 ROW: BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 174
TABLE 204 ROW: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 174
TABLE 205 ROW: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 206 ROW: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 207 ROW: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 175
TABLE 208 ROW: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 176
10.5.1 LATIN AMERICA 176
10.5.1.1 Research funding and rising awareness of advanced sequencing technologies to drive market 176
TABLE 209 LATIN AMERICA: BIOMARKERS MARKET, BY 12 COMPANY PROFILES 196
12.1 KEY PLAYERS 196
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 MERCK KGAA 196
TABLE 227 MERCK KGAA: BUSINESS OVERVIEW 196
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2021) 197
TABLE 228 OTHER DEVELOPMENTS 199
12.1.2 F. HOFFMANN-LA ROCHE LTD. 201
TABLE 229 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 201
FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021) 202
12.1.3 ABBOTT LABORATORIES 206
TABLE 230 ABBOTT LABORATORIES: BUSINESS OVERVIEW 206
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 207
12.1.4 QIAGEN N.V. 210
TABLE 231 QIAGEN N.V.: BUSINESS OVERVIEW 210
FIGURE 36 QIAGEN N.V.: COMPANY SNAPSHOT (2021) 211
12.1.5 THERMO FISHER SCIENTIFIC INC. 215
TABLE 232 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 215
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021) 216
12.1.6 PERKINELMER, INC. 220
TABLE 233 PERKINELMER, INC.: BUSINESS OVERVIEW 220
FIGURE 38 PERKINELMER, INC.: COMPANY SNAPSHOT (2021) 221
12.1.7 BIO-RAD LABORATORIES, INC. 223
TABLE 234 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 223
FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 224
12.1.8 ENZO BIOCHEM, INC. 226
TABLE 235 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW 226
FIGURE 40 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2022) 227
12.1.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 229
TABLE 236 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW 229
FIGURE 41 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021) 230
12.1.10 EUROFINS SCIENTIFIC 231
TABLE 237 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 231
FIGURE 42 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021) 231
12.1.11 MESO SCALE DIAGNOSTICS, LLC 233
TABLE 238 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW 233
12.1.12 STRESSMARQ BIOSCIENCES INC. 234
TABLE 239 STRESSMARQ BIOSCIENCES INC.: BUSINESS OVERVIEW 234
12.1.13 AGILENT TECHNOLOGIES, INC. 235
TABLE 240 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 235
FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021) 236
12.1.14 JOHNSON & JOHNSON 238
TABLE 241 JOHNSON & JOHNSON: BUSINESS OVERVIEW 238
FIGURE 44 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2021) 239
12.1.15 DIAMETRA 240
TABLE 242 DIAMETRA: BUSINESS OVERVIEW 240
12.1.16 SIGNOSIS, INC. 242
TABLE 243 SIGNOSIS, INC.: BUSINESS OVERVIEW 242
12.2 OTHER PLAYERS 243
12.2.1 SINGULEX, INC. 243
TABLE 244 SINGULEX, INC.: BUSINESS OVERVIEW 243
12.2.2 BIOM?RIEUX SA 243
TABLE 245 BIOM?RIEUX SA: BUSINESS OVERVIEW 243
12.2.3 CISBIO BIOASSAYS 244
TABLE 246 CISBIO BIOASSAYS: BUSINESS OVERVIEW 244
12.2.4 EKF DIAGNOSTICS HOLDINGS, PLC 244
TABLE 247 EKF DIAGNOSTICS HOLDINGS, PLC: BUSINESS OVERVIEW 244
12.2.5 MICROCONSTANTS, INC. 245
TABLE 248 MICROCONSTANTS, INC.: BUSINESS OVERVIEW 245
12.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC. 246
TABLE 249 NORTHEAST BIOANALYTICAL LABORATORIES LLC.: BUSINESS OVERVIEW 246
12.2.7 JSR LIFE SCIENCES, LLC 247
TABLE 250 JSR LIFE SCIENCES, LLC: BUSINESS OVERVIEW 247
12.2.8 BIOAGILYTIX LABS 248
TABLE 251 BIOAGILYTIX LABS: BUSINESS OVERVIEW 248
12.2.9 CELERION 248
TABLE 252 CELERION: BUSINESS OVERVIEW 248
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 249
13.1 DISCUSSION GUIDE 249
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 252
13.3 CUSTOMIZATION OPTIONS 254
13.4 RELATED REPORTS 254
13.5 AUTHOR DETAILS 255